Research location
Harlow
Essex, United Kingdom
Advertisement
Research activity in Harlow
Essex, United KingdomCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Harlow
9 linked trials · page 1 of 1Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)NCT03888066 · 2019-04-24 · 1 site observation
COMPLETED
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionNCT03850782 · 2019-02-28 · 1 site observation
COMPLETED
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerNCT03098030 · 2017-06-01 · 1 site observation
COMPLETED
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid ArthritisNCT02744755 · 2016-03-31 · 1 site observation
COMPLETED
TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)NCT01888601 · 2014-04-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Coronary Heart Disease Risk in Type 2 DiabetesNCT01891786 · 2013-07-01 · 1 site observation
COMPLETED
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast CancerNCT00435409 · 2007-02-01 · 1 site observation
COMPLETED
Rebif Compliance Support Program - Assessing Needs in Multiple SclerosisNCT01080573 · 2007-01-01 · 1 site observation
COMPLETED
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyNCT00268476 · 2005-07-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.